

## Bod announces placement to raise \$1.9m

- Bod Science has received firm commitments for an A\$1.9 million Placement at an offer price of A\$0.08
- Proceeds will be used for research and development and working capital
- Placement participants will be offered one attaching option for every two new shares issued, exercisable at \$0.10 on or before 30 June 2024

**Sydney, Australia – 3 August 2023:** Cannabis focused drug development and product innovation company Bod Science Limited (“Bod” or “the Company”) (ASX: BOD) is pleased to announce that it has received firm commitments from professional and sophisticated investors for a placement of new, fully paid ordinary shares (“Shares”) to raise approximately \$1.9 million (“Placement”).

### Management commentary:

**CEO Ms Jo Patterson said:** “We are incredibly pleased with the support we’ve received from new and existing investors. We are on the precipice of an exciting chapter where we will now turn our attention to completing the Phase IIB clinical trial, obtaining ARTG registration and commercialising our uniquely developed CBD product for insomnia.

“I’d like to take this opportunity to thank existing shareholders, and welcome new investors to the Bod Science register.”

### Placement Details

The Placement will raise \$1.9 million (before costs), subject to the Company’s shareholders approving the Director Placement component of the Placement (refer below). The Placement comprises the issue of approximately 24.1 million Shares at the offer price of A\$0.08 per New Share (“Offer Price”). Participants in the Placement will also be offered one unlisted free attaching option for every two Shares allocated in the Placement, with an exercise price of \$0.10 per option and an expiry date of 30 June 2024 (“Attaching Options”).

A total of approximately 22.2 million Shares and 11.1 million Attaching Options will be issued under the Placement using the Company’s existing capacity under ASX Listing Rules 7.1 and 7.1A.

A total of A\$150,000 worth of Shares out of the \$1.9 million to be raised (1.875 million Shares) have been subscribed for at the Offer Price by Bod Chair, Mr David Baker. (“Director Placement”). The Director Placement component of the Placement is conditional on shareholder approval for the purposes of ASX Listing Rule 10.11.

### Use of Funds

The Placement proceeds will be utilised for research and development costs and general working capital.

### Indicative Timetable

Event	Proposed Date
Trading halt	Tuesday, 1 August 2023
Placement announced, trading halt lifted	Thursday, 3 August 2023
Settlement of the Placement	Wednesday, 9 August 2023
Allotment and trading of New Shares under the Placement	Thursday, 10 August 2023
Settlement of Director Placement <sup>1</sup>	Late November 2023
Issue of Shares under Director Placement <sup>1</sup>	Late November 2023

*The timetable is indicative only and subject to change. Bod reserves the right to alter the dates at its full discretion without prior notice, subject to the ASX Listing Rules and the Corporations Act.*

<sup>1</sup> Subject to approval at the AGM

Further information regarding the Company and the Placement, including a description of the risks associated with an investment in Bod, can be found in an investor presentation lodged with ASX today.

Taylor Collison Limited is acting as lead manager of the Placement. The Placement is not underwritten.

**This announcement has been approved by the Board of Bod Science Limited.**

**-ENDS-**

**About Bod Science:**

Bod Science (ASX:BOD) is a cannabis focused drug development and product innovation company.

Bod is focused on progressing research and development with a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for patients and consumers.

The company has a number of existing partnerships with large corporate companies and collaborations with leading research organisations to advance the use of Cannabis related medicines with therapeutic indications.

**For more information please contact:**

Jo Patterson  
Chief Executive Officer  
Info@bodaustralia.com  
+61 2 9199 5018

Amalie Schreurs  
White Noise Communications  
amalie@whitenoisecomms.com  
+61 431 636 033